Nurses, pharmacists rank highest in Gallup poll measuring honesty and high ethical standards
WASHINGTON — Since 2005, more than 80% of Americans have rated nurses as having "high" or "very high" honesty and ethical standards, Gallup noted Monday with the release of its latest ethics poll. Pharmacists ranked No. 2 with 70% of Americans associating the profession with honesty and high ethics.
“We applaud pharmacists for once again achieving an impressive level of confidence and trust from the American public," said Douglas Hoey, CEO National Community Pharmacists Association. "The combination of their goodwill with consumers, extensive training, medication expertise and easy accessibility has pharmacists perfectly positioned to play a larger role in the U.S. healthcare system," Hoey said. "Emerging new care models such as accountable care organizations should fully integrate pharmacists. In addition, policymakers and plan sponsors should better utilize pharmacists’ public standing and knowledge to improve health outcomes and reduce costs, such as through the provision of medication adherence services and medication therapy management.”
In the past, pharmacists and grade school teachers have received high marks on honesty and ethics that are similar to this year’s scores.
This year’s poll was conducted Dec. 5-8. Gallup has asked Americans to rate the honesty and ethical standards of members of various professions periodically since 1976, and annually since 1990.
Endo acquires NuPathe for $105 million
MALVERN, Pa. – Endo Health Solutions will acquire the maker of a patch used to treat migraines that received Food and Drug Administration approval at the beginning of this year.
Endo said Monday that it would buy NuPathe for $105 million. In January, the FDA approved NuPathe’s patch, Zecuity, a disposable, single-use, battery-powered transdermal patch that delivers the drug sumatriptan, the most widely prescribed migraine medication.
"The acquisition of NuPathe enhances our branded pharmaceutical portfolio and is well-aligned with our strategy of acquiring late-stage products for commercialization," said Endo president and CEO Rajiv De Silva. "We’re excited about the opportunity to launch Zecuity, a treatment that could be an option for millions of migraine patients, including those with migraine-related nausea."
Everett Labs acquires Quinnova Pharmaceuticals from Amneal Enterprises
CHATHAM, N.J. — Everett Labs has acquired Quinnova Pharmaceuticals from Amneal Enterprises, Everett said Monday.
Everett Labs, a subsidiary of Spain-based Exeltis, said the purchase would help it expand into the U.S. dermatology and women’s health markets. Financial terms of the deal were not disclosed.
"We believe dermatology is a very attractive opportunity for Everett in the U.S. market, and after an extensive search, we found Quinnova to be a great organization to help us grow this business," Everett Labs CEO Lucas Sigman said. "Quinnova offers important synergies for Everett with its innovative and entrepreneurial culture, as well as its dedicated and focused sales team, which is similar to Everett."